Across TCGA pan-cancer cohorts, RBM43 mass-spec protein is linked to patient survival in 5 of 34 cancer types, making it a survival-associated RBM43 data layer compared with 28 for mass-spec protein and 2 for mutation status.

The strongest signal is observed in lung squamous cell carcinoma (LSCC), where higher RBM43 mass-spec protein is associated with worse disease-free survival. In most high-consensus cancer types, elevated RBM43 expression acts as an unfavorable survival marker, although some lineages such as LUAD show a favorable association.

LSCC, GBM, and LUAD are the cancer types where RBM43 mass-spec protein most reproducibly stratifies survival.

mass-spec protein survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
LSCC	DFS	Median	II,III,IV	0.444	0.864	<.001	39	view →
GBM	DFS	Tertile	All	0.166	0.733	.017	12	view →
LUAD	DFS	Median	All	0.837	0.379	.006	9	view →
PDAC	DFS	Tertile	II,III,IV	0.319	0.699	.027	3	view →
CCRCC	OS	Quartile	All	0.879	1.000	.038	1	view →

Pink = unfavorable, green = favorable. Showing the 5 strongest of 5 lineages.

Exploration

Same gene, other analysis: RBM43 tumor-vs-normal RNA expression · all RBM43 data types